Cargando…

470. Relapsing COVID-19 Pneumonia in Patients Receiving Rituximab Therapy

BACKGROUND: Rituximab is a monoclonal antibody against the CD20 antigen on B-lymphocytes leading to B-cell death and depletion. Patients who receive rituximab and are infected with the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) causing coronavirus disease (COVID-19) may have i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallagher, Jolie, Hall, Kevin H, Albrecht, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644895/ http://dx.doi.org/10.1093/ofid/ofab466.669

Ejemplares similares

470. The Effects of Arrival Quarantine on Subsequent COVID-19 Testing in a Cohort of Military Basic Trainees
por: Marcus, Joseph E, et al.
Publicado: (2020)

Rituximab: Relapse or exacerbation of COVID-19 pneumonia: 4 case reports
Publicado: (2022)

P1565: INCIDENCE OF PNEUMOCYSTIS JIROVECII PNEUMONIA IN PATIENTS WITH B-LINEAGE LYMPHOMA RECEIVING CHEMOTHERAPY CONTAINING RITUXIMAB
por: Liang, Xiping Xiping, et al.
Publicado: (2023)

416. Poor clinical outcomes of COVID-19 patients receiving rituximab during the Omicron era
por: Lee, Chan Mi, et al.
Publicado: (2023)

P470: SINGLE-CELL METABOLIC MULTIOMICS TO IDENTIFY VULNERABILITIES IN ACUTE MYELOID LEUKEMIA STEM CELLS
por: Antes, Magdalena, et al.
Publicado: (2023)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

545. A Retrospective Review of 30-day Mortalities in Solid-Organ Transplant Recipients (SOT) versus Non-Transplant Patients (NTP) Receiving Remdesivir (REM) and Dexamethasone (DEX) for COVID-19 Pneumonia
por: Vyas, Krina, et al.
Publicado: (2021)

342. Secondary Infections following Tocilizumab for Treatment of COVID-19 Pneumonia
por: Warner, Adam, et al.
Publicado: (2021)

The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy
por: Ekin, Ali, et al.
Publicado: (2022)

376. COVID-19 Severity in HIV+ Patients Receiving Tenofovir
por: Homsi, Nora, et al.
Publicado: (2020)

336. COVID-19 and Pneumocystis jiroveci Pneumonia
por: Saling, Christopher, et al.
Publicado: (2021)

Amdahl 470 Chip Package
Publicado: (1975)

280. Burden of Hyperglycemia in Patients Receiving Dexamethasone for Severe COVID-19
por: Fetters, Kirk B, et al.
Publicado: (2021)

P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL
por: Zinzani, P. L., et al.
Publicado: (2022)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

P64 A CASE OF COVID-19 PNEUMONIA AFTER CAR T-CELL THERAPY IN A PATIENT AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Ielo, C., et al.
Publicado: (2023)

493. Incidence and Characterization of Chronic Active COVID Among Patients Infected with the Novel Coronavirus (COVID-19) Receiving B-cell Depleting Therapies (BCDTs)
por: Kartes, Jacob, et al.
Publicado: (2021)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
por: Sehn, L. H., et al.
Publicado: (2022)

470. Concomitant Antibiotic Use and Death Among a National Cohort of Veterans With Clostridium difficile Infection (CDI)
por: Appaneal, Haley, et al.
Publicado: (2018)

1311. Intrapulmonary Pharmacokinetics of Cefiderocol in Hospitalized and Ventilated Patients Receiving Standard of Care Antibiotics for Bacterial Pneumonia
por: Katsube, Takayuki, et al.
Publicado: (2020)

400. Secondary Infections in COVID-19 Patients Receiving Tocilizumab in a Community Hospital
por: Usiak, Shauna, et al.
Publicado: (2020)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Séminaire Bourbaki : exposés 453–470
por: Collective
Publicado: (1976)

P1105: FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM-R2 STUDY INCLUDING 2-YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENSTRÖM’S MACROGLOBULINEMIA
por: Dimopoulos, M.-A., et al.
Publicado: (2022)

P1664: IMPACT OF A PROTOCOL USING RITUXIMAB FOR PREVENTION OF RELAPSE IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP)
por: Marín Sánchez, E., et al.
Publicado: (2022)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Zhang, Xiyuan, et al.
Publicado: (2023)

470 COVID-19 Experience in New South Wales (NSW) - A Case Series
por: Rao, A., et al.
Publicado: (2020)

345. Dermatological Manifestations in Patients with COVID-19 Pneumonia in Veracruz, Mexico
por: Del Carpio-Orantes, Luis, et al.
Publicado: (2021)

Neoehrlichia mikurensis Causing Thrombosis and Relapsing Fever in a Lymphoma Patient Receiving Rituximab
por: Sjöwall, Johanna, et al.
Publicado: (2021)

53. Incidence of Bloodstream Infections and Outcomes in Patients with Severe COVID-19 Pneumonia
por: Papamanoli, Aikaterini, et al.
Publicado: (2020)

498. Baricitinib in Patients with Severe Pneumonia due to COVID-19 in Veracruz, Mexico
por: Del Carpio-Orantes, Luis, et al.
Publicado: (2021)

80. The Utility of Cultures for Isolated Fevers in Patients with Influenza or COVID-19 Receiving Extracorporeal Membrane Oxygenation
por: Marcus, Joseph E, et al.
Publicado: (2021)

341. Evaluation of Antimicrobial Use and Prescribing Patterns During the COVID-19 Pandemic in Patients Receiving Tocilizumab
por: Barsoum, Barbara, et al.
Publicado: (2021)

296. Description of Super-infections in Hospitalized Patients with COVID-19
por: Kludjian, Geena, et al.
Publicado: (2021)

Oral Antiviral Therapy and Monoclonal Antibody for the Treatment of COVID-19 Infection in Outpatients Receiving Anti-Cancer Treatment for Hematological Malignancies: A Multicenter Prospective Study Exploring Efficacy, Safety and Predictors of COVID-19 Lung Failure
por: Minoia, Carla, et al.
Publicado: (2022)

P1200: RELAPSE AND OCCURRENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RITUXIMAB ERA, A NATIONWIDE OBSERVATIONAL STUDY
por: Lee, H. J., et al.
Publicado: (2022)

Prednisone/rituximab: COVID-19 pneumonia: case report
Publicado: (2021)

Bendamustine/rituximab: COVID-19 pneumonia: case report
Publicado: (2021)

374. Complication with Bacterial Pneumonia in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19)
por: Kang, Minji, et al.
Publicado: (2020)

76. Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with COVID-19 Pneumonia
por: Papamanoli, Aikaterini, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6s6b4ll1dga80ftimhq7b2ubt5